文献速递甲状腺疾病

甲状腺乳头状癌低核分裂活性:侵袭性特征与复发的标志物

Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

单机构2018至2022年连续640例甲状腺乳头状癌(PTC)回顾性分析,按世界卫生组织标准分为无、低(1-2个核分裂/2 mm²)、高(≥3个核分裂/2 mm²)核分裂活性。低核分裂活性PTC的中间/高危美国甲状腺协会(ATA)风险分层比例及复发率均高于无核分裂活性者,且低核分裂活性与复发相关,独立于ATA风险分层(HR 2.96;95%CI 1.28-6.87,P=.01)。

要点

  • 低核分裂活性PTC的中间/高危ATA风险分层比例高于无核分裂活性者(P<.001)。
  • 低核分裂活性PTC复发率15.5%,高于无核分裂活性者的4.5%(P<.001)。
  • 低核分裂活性与复发相关,独立于ATA风险分层(HR 2.96;95%CI 1.28-6.87,P=.01)。

核心结论

  • 低核分裂活性在PTC中相对常见,其行为介于无和高核分裂活性之间,与侵袭性临床病理特征和复发相关,在PTC复发风险分层时应考虑低核分裂活性。

研究设计与样本

  • 单机构2018至2022年连续PTC患者系列回顾性分析,共纳入640例PTC。
  • 核分裂活性按世界卫生组织标准定义:无核分裂、低(1-2个核分裂/2 mm²)、高(≥3个核分裂/2 mm²)。
  • 应用2015年美国甲状腺协会(ATA)风险分层,比较组间临床病理特征;对随访≥6个月的患者行复发Cox回归分析。

主要发现

  • 640例PTC中,无核分裂活性515例(80.5%),低核分裂活性110例(17.2%),高核分裂活性15例(2.3%)。
  • 低核分裂活性PTC的血管侵犯、大体甲状腺外侵犯和淋巴结转移率介于无和高核分裂活性之间。
  • 低核分裂活性PTC的中间和高危ATA风险分层比例高于无核分裂活性者(P<.001)。
  • 低核分裂活性PTC复发率为15.5%,无核分裂活性者为4.5%(P<.001)。
  • 低核分裂活性与复发相关,独立于ATA风险分层(HR 2.96;95%CI 1.28-6.87,P=.01)。

关键数值与推荐

  • 核分裂活性定义:无核分裂、低(1-2个核分裂/2 mm²)、高(≥3个核分裂/2 mm²),依据世界卫生组织标准。
  • 风险分层采用2015年美国甲状腺协会(ATA)风险分层。

临床怎么用

  • 原文结论认为,鉴于低核分裂活性与侵袭性临床病理特征和复发相关,在PTC患者复发风险分层时应考虑低核分裂活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The significance of low mitotic activity in papillary thyroid cancer (PTC) is largely undefined. OBJECTIVE: We aimed to determine the behavioral landscape of PTC with low mitotic activity compared with that of no and high mitotic activity. METHODS: A single-institution consecutive series of patients with PTC from 2018 to 2022 was reviewed. Mitotic activity was defined as no mitoses, low (1-2 mitoses/2 mm2) or high (≥3 mitoses/2 mm2) per the World Health Organization. The 2015 American Thyroid Association risk stratification was applied to the cohort, and clinicopathologic features were compared between groups. For patients with ≥6 months of follow-up, Cox regression analyses for recurrence were performed. RESULTS: A total of 640 PTCs were included-515 (80.5%) no mitotic activity, 110 (17.2%) low mitotic activity, and 15 (2.3%) high mitotic activity. Overall, low mitotic activity exhibited rates of clinicopathologic features including vascular invasion, gross extrathyroidal extension, and lymph node metastases in between those of no and high mitotic activity. PTCs with low mitotic activity had higher rates of intermediate- and high-risk American Thyroid Association (ATA) risk stratification compared with those with no mitotic activity (P < .001). Low mitotic activity PTCs also had higher recurrence rates (15.5% vs 4.5%, P < .001). Low mitotic activity was associated with recurrence, independent of the ATA risk stratification (HR 2.96; 95% CI 1.28-6.87, P = .01). CONCLUSION: Low mitotic activity is relatively common in PTC and its behavior lies within a spectrum between no and high mitotic activity. Given its association with aggressive clinicopathologic features and recurrence, low mitotic activity should be considered when risk stratifying patients with PTC for recurrence.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lee-Saxton YJ, Egan CE, Bratton BA, et al. Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence. J Clin Endocrinol Metab. 2025. PMID: 38554391. doi:10.1210/clinem/dgae203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。